Scopus Biopharma: Soars as FDA approves trial of lead cancer therapy candidate

Scopus Biopharma

24/05/2021 15:21

** Biotech co's shares  SCPS.O  more than double to $13.33
    ** Co says the U.S. FDA approves investigational new drug
application for its lead immuno-oncology RNA therapy to treat
multiple cancers  urn:newsml:reuters.com:*:nGNX1znnmj
    ** The treatment will be studied in an early-stage clinical
trial for a type of cancer called B-cell non-Hodgkin lymphoma -
co
    ** Co says the drug, which works by targeting specific
genes, was developed at cancer research center City of Hope
    ** SCPS stock down about 34% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))